Description

IDEXX Lab’s Installed Base Advantage Is Getting Stronger — And It’s Showing Up in Utilization!

IDEXX Laboratories, in its fourth quarter of 2025, showcased a robust financial performance with significant growth across its core business sectors. The company reported a 14% increase in total revenue for the quarter, with 12% growth on an organic basis, primarily driven by the Companion Animal Group (CAG) Diagnostics recurring revenues, which grew organically by 10%. This growth was strengthened by the record placement of premium instruments, notably the IDEXX inVue Dx, leading to a 69% organic growth in CAG Diagnostic instrument revenues. Despite external pressures on clinical visits in the U.S., IDEXX Laboratories outperformed sector trends by achieving a growth premium of approximately 1,100 basis points compared to U.S. clinical visit growth levels, which faced declines. The company’s international operations also contributed significantly, with double-digit growth in both CAG Diagnostics and water revenue sectors, highlighting the global demand for IDEXX’s diagnostic solutions.